Urodart0.5 mg

Urodart is a 5-alpha reductase inhibitor used mainly in the management of an enlarged prostate gland in men.

Established / FDA-approved uses

• Benign Prostatic Hyperplasia (BPH), monotherapy: Urodart is indicated for the treatment of symptomatic BPH in men with an enlarged prostate, to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery.
• BPH, combination therapy: Urodart is also indicated in combination with the alpha-blocker tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.

Off-label use

• Male pattern hair loss (androgenetic alopecia): Urodart, usually at a low dose, is commonly used off-label by dermatologists/urologists for male pattern baldness. This use is not FDA-approved; it should only be undertaken under a physician's supervision after discussing the risks (including sexual side effects) versus benefits.

Urodart is not indicated and should not be used for the prevention of prostate cancer, and it is not indicated for use in women or children.

Each capsule contains Dutasteride as the active pharmaceutical ingredient, together with pharmaceutically acceptable excipients. Dutasteride is typically formulated as a soft gelatin capsule for oral use.

Urodart is a synthetic 4-azasteroid compound that belongs to the class of 5-alpha reductase inhibitors. It works by blocking the conversion of testosterone to the more potent androgen dihydrotestosterone (DHT), which is a key driver of prostate gland enlargement. By lowering DHT levels, Urodart helps shrink the enlarged prostate over time, improves urinary symptoms associated with benign prostatic hyperplasia (BPH), and reduces the long-term risk of acute urinary retention and the need for prostate-related surgery.

Urodart is taken orally, once daily, and its full clinical benefit typically develops gradually over three to six months of continuous use.

Urodart belongs to the therapeutic class of 5-alpha reductase inhibitors (dual inhibitor of Type 1 and Type 2 isoenzymes), used in the medical management of benign prostatic hyperplasia.

Mechanism of action: Dutasteride is a selective inhibitor of both the Type 1 and Type 2 isoforms of the enzyme 5-alpha reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). DHT is the principal androgen responsible for the initial development and subsequent hyperplastic growth of prostate tissue. By inhibiting both isoenzymes, Dutasteride produces a greater suppression of serum DHT (approximately 90-95% reduction) compared with selective Type 2 inhibitors.

Pharmacokinetics

• Absorption: Well absorbed after oral administration; peak plasma concentration reached in 1-3 hours.
• Distribution: Extensively bound to plasma proteins (>99%); large volume of distribution due to high lipophilicity.
• Metabolism: Extensively metabolized in the liver, primarily via the CYP3A4 and CYP3A5 isoenzymes.
• Elimination: Has a very long elimination half-life (approximately 3-5 weeks) with chronic dosing; primarily excreted via feces, with a small amount in urine. It can remain detectable in serum for up to 4-6 months after stopping treatment.

Urodart capsules should be swallowed whole with a glass of water and must not be crushed, chewed, or opened, as contact with the liquid contents of the capsule may cause irritation of the lips, mouth, and throat. Urodart may be taken with or without food, at approximately the same time each day to help maintain consistent blood levels.

Women, especially those who are or may become pregnant, should avoid handling leaking or damaged Urodart capsules. If contact does occur, the area should be washed immediately with soap and water.

Urodart is metabolized mainly by the CYP3A4 enzyme, so drugs that strongly inhibit this enzyme can raise blood levels of Urodart and potentially increase the risk of side effects.

Urodart is not known to significantly affect the metabolism of other commonly co-administered drugs such as warfarin or digoxin, but routine clinical monitoring is still advisable when starting or stopping therapy.

The most common side effects of Urodart are related to sexual function and generally occur more frequently during the first year of treatment.

In some patients, sexual side effects such as decreased libido and erectile dysfunction have been reported to persist even after Urodart is discontinued. Patients experiencing this should discuss it with their physician.

Urodart is contraindicated in women and must never be used, or even handled in its leaking/damaged capsule form, by women who are pregnant or who could become pregnant. Urodart is absorbed through the skin, and exposure of a female fetus in utero, or of a male fetus, to Urodart can cause abnormalities of the external genitalia. This is a well-established teratogenic risk (legacy pregnancy category X).

Pregnant women or women who could become pregnant should avoid any contact with leaking or crushed Urodart capsules; if accidental contact occurs, the area should be washed immediately with soap and water, and a physician should be contacted.

Urodart is not indicated for use in women, so lactation is not applicable to this medicine.

• Effect on PSA (Prostate-Specific Antigen): Urodart lowers serum PSA levels by approximately 50% after about 6 months of treatment, even in the absence of prostate cancer. A new PSA baseline should be established after 3-6 months of use, and any confirmed increase from the lowest on-treatment PSA value should be evaluated by the physician, even if PSA levels remain within the range normally considered to be free of prostate cancer, as this may indicate the presence of prostate cancer or non-compliance with Urodart therapy.
• High-grade prostate cancer: An increased occurrence of high-grade prostate cancer has been reported in men taking 5-alpha reductase inhibitors, including Urodart, in some clinical studies. Patients should discuss this risk with their prescribing physician.
• Sexual side effects: Decreased libido, erectile dysfunction, and ejaculation disorders can occur and may persist after stopping Urodart in some patients (see Side Effects).
• Blood donation: Men being treated with Urodart should not donate blood until at least 6 months after their last dose, to prevent Urodart exposure in a pregnant transfusion recipient, which could harm a male fetus.
• Hepatic impairment: Use with caution, as Urodart is extensively metabolized by the liver and has not been formally studied in hepatic impairment.
• Breast changes: Patients should report any lumps, pain, nipple discharge, or enlargement of breast tissue promptly, as these could be signs of male breast cancer, which has been reported rarely.

There is no specific antidote for Urodart overdose. Single doses of up to 40 mg/day (80 times the therapeutic dose) have been given for short periods in clinical studies without serious safety concerns, but this does not guarantee safety in all individuals. If an overdose of Urodart is suspected, seek immediate medical attention or contact a poison control center; treatment should be symptomatic and supportive, as directed by a physician.

Store at room temperature (below 30°C), away from light and moisture, in the original container. Keep out of reach of children and away from women, especially those who are or may become pregnant.

• Women: Urodart is contraindicated in women of any age (see Contraindications and Pregnancy and Lactation).
• Pediatric patients: Safety and efficacy have not been established; Urodart is not indicated in children.
• Elderly: No dose adjustment is required based on age alone; BPH primarily affects older men, who form the main treated population.
• Renal impairment: No dose adjustment is generally required (see Dosage and Administration).
• Hepatic impairment: Use with caution; not formally studied (see Precautions and Warnings).

Urodart is generally used as a long-term, continuous therapy for BPH, since prostate size and symptoms tend to recur if treatment is stopped. Clinical response should be reassessed periodically (e.g., every 3-6 months and then annually) by the prescribing physician. When used off-label for hair loss, duration is likewise long-term and should be guided by the treating physician.

5-alpha reductase inhibitors

Dutasteride works by blocking both the Type 1 and Type 2 isoforms of the 5-alpha reductase enzyme, which converts testosterone into dihydrotestosterone (DHT). Because DHT is the main hormone driving prostate tissue growth, this dual inhibition markedly lowers DHT levels in the blood and prostate, leading to shrinkage of the enlarged prostate gland and improvement of urinary symptoms over time.

X

Urodart is not indicated for use in pediatric patients. The safety and efficacy of Urodart in children have not been established, and Urodart must not be given to, or handled by, children.